<DOC>
	<DOCNO>NCT01165580</DOCNO>
	<brief_summary>This open label study ass pharmacokinetics safety tolerability Valcyte ( valganciclovir ) powder oral solution neonatal infant heart transplant patient &lt; 4 month age .</brief_summary>
	<brief_title>A Study Pharmacokinetics Safety Valcyte ( Valganciclovir ) Pediatric Heart Transplant Recipients Less Than 4 Months Age</brief_title>
	<detailed_description />
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Valganciclovir</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<criteria>Males female , 0 &lt; 4 month ( &lt; 125 day ) age time last PK assessment study Parent guardian patient willing able give write informed consent Patient receive first heart transplant Patient risk develop cytomegalovirus ( CMV ) disease treat i.v . ganciclovir oral valganciclovir prevention CMV Adequate hematological renal function Able tolerate oral medication ( appropriate form tube feed acceptable ) Allergic significant adverse reaction acyclovir , valacyclovir ganciclovir past Severe , uncontrolled , clinically abnormal diarrhea Liver enzyme elevation five time upper limit normal AST ( SGOT ) ALT ( SGPT ) Patient require use protocol prohibit concomitant medication Patient previously participate clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>124 Days</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>